Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 27, 2012
Last updated: August 1, 2016
Last verified: August 2016
This observational study will evaluate the efficacy and safety of different Xeloda (capecitabine) based chemotherapies, alone or in combination with Avastin (bevacizumab), in first line in patients with metastatic colorectal cancer.

Colorectal Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival with different Xeloda-based chemotherapy regimens [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Objective response rate (complete response + partial response) [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Clinical benefit rate (complete response + partial response + stable disease) [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Metastasectomy rate [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Mean duration of Xeloda treatment [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Dose modification rate for Xeloda [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]

Enrollment: 882
Study Start Date: July 2011
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with newly diagnosed colorectal cancer who have started first-line capecitabine (Xeloda) based chemotherapy alone or in combination with bevacizumab (Avastin)

Inclusion Criteria:

  • Patients with newly diagnosed metastatic colorectal cancer who have started first-line Xeloda-based chemotherapy in accordance with the current Hungarian label

Exclusion Criteria:

  • History of serious or unexpected reaction to fluoropyrimidine therapy
  • Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of the product, or to fluorouracil
  • Known dihydropyrimidine dehydrogenase deficiency
  • Pregnancy or lactation
  • Inadequate bone marrow, hepatic or renal function
  • Treatment with sorivudine or its chemical analogues (e.g. brivudine)
  • If any contraindication for any drug used in the combination treatment schedules is present, the drug in question cannot be used
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01696695

Budapest, Hungary, 1032
Budapest, Hungary, 1076
Budapest, Hungary, 1088
Budapest, Hungary, 1125
Budapest, Hungary, 1145
Debrecen, Hungary, 4031
Gyor, Hungary, 9024
Gyula, Hungary, 5700
Kecskemet, Hungary, 6000
Kistarcsa, Hungary, 2143
Miskolc, Hungary, 3501
Nyíregyháza, Hungary, 4400
Pecs, Hungary, 7623
Salgótarján, Hungary, 3100
Szeged, Hungary, 6720
Szekesfehervar, Hungary, 8000
Szekszard, Hungary, 7100
Szentes, Hungary, 6600
Szombathely, Hungary, 9700
Tatabanuya, Hungary, 2800
Veszprem, Hungary, 8200
Zalaegerszeg, Hungary, 8900
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01696695     History of Changes
Other Study ID Numbers: ML27791 
Study First Received: September 27, 2012
Last Updated: August 1, 2016
Health Authority: Hungary: National Instutute of Pharmacy

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on September 30, 2016